Composite formulation for oral dosage comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxyl acid
The present invention relates to a composite formulation for oral dosage that comprises an API selected from 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof and does not comprise a pH modifier as an excipient. Since the composite formulation...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | The present invention relates to a composite formulation for oral dosage that comprises an API selected from 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof and does not comprise a pH modifier as an excipient. Since the composite formulation for oral dosage according to the present invention does not comprise a pH modifier, it has the advantage of having a high level of dissolution rate as well as enhanced dosing convenience and productivity, in spite of comprising a high content of API. |
|---|